DreyfussA.I., ClarkJ.K., NorrisC.M.: Docetaxel, an active drug for squamous cell carcinoma of the head and neck.J Clin Oncol14: 1672–1678, 1996.
2.
CouteauC., LeyvrazS., Oulid-AissaD.: A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.Br J Cancer81: 457–462, 1999.
3.
EbibaraS., FujiiH., SasakiY.: A late phase II study of docetaxel in patients with head and neck cancer.Proc ASCO16: 1425 (abst), 1997.
4.
SchoffskiP., CatimelG., PlantingA.S. for the EORTC and ECSG: Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC.Ann Oncol10: 119–122, 1999.
5.
ColevasA.D., BusseP.M., NorrisC.M.: Induction chemotherapy with docetaxel, cisplatin, fluouracil and leucovorin for squamous cell carcinoma of the head and neck. A phase I/II trial.J Clin Oncol16: 1331–1339, 1998.
6.
ColevasA.D., NorrisC.M., TishlerR.B.: Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.J Clin Oncol17: 3503–3511, 1999.
7.
PosterM.R., GlissonB., FrenetteG.: Multicenter phase I-II trial of docetaxel, cisplatin and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.J Clin Oncol4: 1096–1104, 2001.
8.
JaninisJ., PapadakouM., PanagosG.: Sequential chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced head and neck cancer.Am J Clin Oncol3: 227–231, 2001.
9.
KourakisMl, BizakisJ.G., SkoulakisL.E.: Combined irinotecan, docetaxel and conventionally fractionated radiotherapy in locally advanced head and neck cancer. A phase I dose escalation study.Anticancer Res19(3B): 2305–2309, 1999.
10.
HesseK., HeinrichB., ZimmermannF.: Combined radiotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors.Strahlenther Onkol176: 67–72, 2000.
11.
HehrT., BudachW., BelkaC.: Alternating radio-chemotherapy with docetaxel/DDP and involved field radiotherapy for recurrent, inoperable, and previously irradiated head and neck.ECCO388(abst), 2001.
